Skip to main content
ROVI Subsidiaries
Spain
Germany
France
Italy
Poland
Portugal
United Kingdom
Language
Spanish
Spanish
English
English
English
Español
Home
ROVI
History
Group structure
Business units
International expansion
Strategy
Licenses
Contact
Products
Prescription Pharmaceuticals
Hospital Products
Manufacturing
CDMO
Own product Manufacturing
R&D
Shareholders and Investors
The share
Investor's Calendar
News
Financial and Business Information
CMNV Communications
ESG
Corporate Governance
Telematic assistance access
Prior Registration On-Line Attendance
On-Line Attendance
Sustainability
Responsible governance
Commitment to people
Environmental Commitment
Ethics Channel
Media
FAQS
News
ROVI up to date
Contact
Work with Us
TELEMATIC ASSISTANCE ACCESS
Home
News
Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone
Tue, 15/09/2020 - 00:00
0 min
Download related document
Select rating
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 1/5
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 2/5
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 3/5
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 4/5
Give Granting of partially refundable aid for the development of a new quarterly formulation of Risperidone 5/5
No votes yet
Related
ROVI plants a forest with 2,000 trees in the Madrid Sierra
Madrid, 27 March 2023 Laboratorios Farmacéuticos ROVI and ReTree are collaborating to plant ROVI’s Forest in the Madrid Sierra. It is an...
3 min
27/03/2023
BioSim strengthens its national representation with the incorporation of ROVI...
Madrid, 21 March 2023 Laboratorios Farmacéuticos ROVI announces its incorporation as a member of the General Assembly of the Spanish...
3 min
21/03/2023
Full Year 2022 Results Press Release
ROVI REPORTS OPERATING REVENUE GROWTH OF 26% AND EBITDA GROWTH OF 37% Operating revenue increased by 26% to 817.7 million euros...
3 min
21/02/2023
See More
Email
Facebook
Twitter
LinkedIn